• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Applications of medicine in treating pulmonary fibrosis.

作者信息

Li Wenjun, Shi Xin, Lv Changjun, Hu Haibo, Sundar Isaac Kirubakaran, Qin Song

机构信息

Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, China.

Shandong Technology and Business University, Yantai, China.

出版信息

Front Pharmacol. 2023 Jul 4;14:1212681. doi: 10.3389/fphar.2023.1212681. eCollection 2023.

DOI:10.3389/fphar.2023.1212681
PMID:37469878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10352825/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cc1/10352825/10ba3fbe3a66/fphar-14-1212681-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cc1/10352825/10ba3fbe3a66/fphar-14-1212681-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cc1/10352825/10ba3fbe3a66/fphar-14-1212681-g001.jpg

相似文献

1
Editorial: Applications of medicine in treating pulmonary fibrosis.社论：医学在治疗肺纤维化中的应用
Front Pharmacol. 2023 Jul 4;14:1212681. doi: 10.3389/fphar.2023.1212681. eCollection 2023.
2
Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects.用于治疗肺纤维化的传统中药：进展与未来展望。
J Ethnopharmacol. 2017 Feb 23;198:45-63. doi: 10.1016/j.jep.2016.12.042. Epub 2016 Dec 28.
3
Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial.新冠肺炎恢复期继发肺纤维化患者采用中西医结合治疗的疗效：一项随机多中心试验。
Infect Dis Poverty. 2021 Mar 18;10(1):31. doi: 10.1186/s40249-021-00813-8.
4
Monomeric compounds from traditional Chinese medicine: New hopes for drug discovery in pulmonary fibrosis.单体化合物来源于中药：肺纤维化药物发现的新希望。
Biomed Pharmacother. 2023 Mar;159:114226. doi: 10.1016/j.biopha.2023.114226. Epub 2023 Jan 17.
5
[Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors].[发现中药复方对VEGFR和FGFR抑制剂治疗COVID-19肺纤维化的干预作用]
Zhongguo Zhong Yao Za Zhi. 2020 Apr;45(7):1481-1487. doi: 10.19540/j.cnki.cjcmm.20200315.401.
6
Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential.中药联合肺部给药系统与特发性肺纤维化：原理与治疗潜力。
Biomed Pharmacother. 2021 Jan;133:111072. doi: 10.1016/j.biopha.2020.111072. Epub 2020 Dec 8.
7
Active Components from Traditional Herbal Medicine for the Potential Therapeutics of Idiopathic Pulmonary Fibrosis: A Systemic Review.传统草药中的活性成分治疗特发性肺纤维化的潜力：系统评价。
Am J Chin Med. 2021;49(5):1093-1114. doi: 10.1142/S0192415X2150052X. Epub 2021 Jun 3.
8
Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula.中药复方抗肝纤维化治疗的研究进展。
J Ethnopharmacol. 2020 Apr 6;251:112442. doi: 10.1016/j.jep.2019.112442. Epub 2019 Dec 28.
9
Ability to Suppress TGF-β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions.抑制转化生长因子-β激活的肌成纤维细胞分化的能力区分了两种含丹参的中药方剂的抗肺纤维化疗效。
Front Pharmacol. 2019 Apr 24;10:412. doi: 10.3389/fphar.2019.00412. eCollection 2019.
10
Multi-Pharmaceutical Activities of Chinese Herbal Polysaccharides in the Treatment of Pulmonary Fibrosis: Concept and Future Prospects.中药多糖治疗肺纤维化的多药效学活性：概念与未来展望
Front Pharmacol. 2021 Aug 17;12:707491. doi: 10.3389/fphar.2021.707491. eCollection 2021.

本文引用的文献

1
Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis.特发性肺纤维化的发病机制。
Annu Rev Pathol. 2022 Jan 24;17:515-546. doi: 10.1146/annurev-pathol-042320-030240. Epub 2021 Nov 23.
2
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.特发性肺纤维化：疾病机制与药物研发。
Pharmacol Ther. 2021 Jun;222:107798. doi: 10.1016/j.pharmthera.2020.107798. Epub 2020 Dec 24.
3
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study.
端粒长度与特发性肺纤维化和慢性阻塞性肺疾病风险：一项孟德尔随机研究。
Lancet Respir Med. 2021 Mar;9(3):285-294. doi: 10.1016/S2213-2600(20)30364-7. Epub 2020 Nov 13.
4
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.特发性肺纤维化的药物治疗：现状与未来潜力。
Eur Respir Rev. 2017 Sep 27;26(145). doi: 10.1183/16000617.0071-2017. Print 2017 Sep 30.
5
Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis.特发性肺纤维化，第 1 部分：流行病学、发病机制和诊断。
Expert Rev Respir Med. 2017 May;11(5):343-359. doi: 10.1080/17476348.2017.1312346. Epub 2017 Apr 10.